RT Journal Article SR Electronic T1 Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders JF Neurology - Neuroimmunology Neuroinflammation JO Neurol Neuroimmunol Neuroinflamm FD Lippincott Williams & Wilkins SP e1060 DO 10.1212/NXI.0000000000001060 VO 8 IS 6 A1 Samira Luisa Apostolos-Pereira A1 Lis Campos Ferreira A1 Mateus Boaventura A1 Nise Alessandra de Carvalho Sousa A1 Gabriela Joca Martins A1 José Arthur d'Almeida A1 Milena Pitombeira A1 Lucas Silvestre Mendes A1 Thiago Fukuda A1 Hideraldo Luíz Souza Cabeça A1 Luciano Chaves Rocha A1 Bianca Santos de Oliveira A1 Carla Renata Vieira Stella A1 Enedina Maria Lobato de Oliveira A1 Leizian de Souza Amorim A1 Andréa Ferrari de Castro A1 Antonio Pereira Gomes Neto A1 Guilherme Diogo Silva A1 Lucas Bueno A1 Maria de Morais Machado A1 Rafael Castello Dias-Carneiro A1 Ronaldo Maciel Dias A1 Alvaro Porto Moreira A1 Ana Piccolo A1 Anderson Kuntz Grzesiuk A1 Andre Muniz A1 Caio Diniz Disserol A1 Claudia Ferreira Vasconcelos A1 Damacio Kaimen-Maciel A1 Denise Sisterolli Diniz A1 Elizabeth Comini-Frota A1 Fernando Coronetti Rocha A1 Gutemberg Augusto Cruz dos Santos A1 Yara Dadalti Fragoso A1 Guilherme Sciascia do Olival A1 Heloisa Helena Ruocco A1 Heloise Helena Siqueira A1 Henry Koity Sato A1 José Alexandre Figueiredo, Jr A1 Leandro Cortoni Calia A1 Mario Emilio Teixeira Dourado, Jr A1 Letícia Scolari A1 Herval Ribeiro Soares Neto A1 Luiz Melges A1 Marcus Vinicius Magno Gonçalves A1 Maria Lucia Vellutini Pimentel A1 Marlise de Castro Ribeiro A1 Omar Gurrola Arambula A1 Paulo Diniz da Gama A1 Renata Leite Menon A1 Rodrigo Barbosa Thomaz A1 Rogério de Rizo Morales A1 Silvana Sobreira A1 Suzana Nunes Machado A1 Taysa Gonsalves Jubé Ribeiro A1 Valéria Coelho Santa Rita Pereira A1 Vanessa Maia Costa A1 Adaucto Wanderley da Nóbrega Junior A1 Soniza Vieira Alves-Leon A1 Marilia Mamprim de Morais Perin A1 Eduardo Donadi A1 Tarso Adoni A1 Sidney Gomes A1 Maria Brito Ferreira A1 Dagoberto Callegaro A1 Maria Fernanda Mendes A1 Doralina Brum A1 Felipe von Glehn A1 , YR 2021 UL http://nn.neurology.org/content/8/6/e1060.abstract AB Background and Objectives To describe the clinical features and disease outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorder (NMOSD).Methods The Neuroimmunology Brazilian Study Group has set up the report of severe acute respiratory syndrome (SARS-CoV2) cases in patients with NMOSD (pwNMOSD) using a designed web-based case report form. All neuroimmunology outpatient centers and individual neurologists were invited to register their patients across the country. Data collected between March 19 and July 25, 2020, were uploaded at the REDONE.br platform. Inclusion criteria were as follows: (1) NMOSD diagnosis according to the 2015 International Panel Criteria and (2) confirmed SARS-CoV2 infection (reverse transcription-polymerase chain reaction or serology) or clinical suspicion of COVID-19, diagnosed according to Center for Disease Control / Council of State and Territorial Epidemiologists (CDC/CSTE) case definition. Demographic and NMOSD-related clinical data, comorbidities, disease-modifying therapy (DMT), COVID-19 clinical features, and severity were described.Results Among the 2,061 pwNMOSD followed up by Brazilian neurologists involved on the registry of COVID-19 in pwNMOSD at the REDONE.br platform, 34 patients (29 women) aged 37 years (range 8–77), with disease onset at 31 years (range 4–69) and disease duration of 6 years (range 0.2–20.5), developed COVID-19 (18 confirmed and 16 probable cases). Most patients exhibited mild disease, being treated at home (77%); 4 patients required admission at intensive care units (severe cases); and 1 patient died. Five of 34 (15%) presented neurologic manifestations (relapse or pseudoexacerbation) during or after SARS-CoV2 infection.Discussion Most NMOSD patients with COVID-19 presented mild disease forms. However, pwNMOSD had much higher odds of hospitalization and intensive care unit admission comparing with the general Brazilian population. The frequency of death was not clearly different. NMOSD disability, DMT type, and comorbidities were not associated with COVID-19 outcome. SARS-CoV2 infection was demonstrated as a risk factor for NMOSD relapses. Collaborative studies using shared NMOSD data are needed to suitably define factors related to COVID-19 severity and neurologic manifestations.AQP4=aquaporin 4; CBA=cell-based assay; CI=confidence interval; COVID-19=coronavirus disease 2019; DMT=disease-modifying therapy; MS=multiple sclerosis; NMOSD=neuromyelitis optica spectrum disorders; OR=odds ratio; pwNMOSD=patients with NMOSD; RT-PCR=reverse transcription-polymerase chain reaction; SARS=severe acute respiratory syndrome